PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.2061
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-To-Severe Psoriasis in the United States

Dermatology and Therapy
Dermatology
2018English

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

Pss30 - Cost Effectiveness of Dimethyl Fumarate (Dmf) in the Treatment of Moderate to Severe Plaque Psoriasis: A Uk Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy83 - Impact of Dose Escalation on Average Cost and Cost-Effectiveness of Anti-TNF and Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PSS14 Economic Analysis of Etanercept as Paused Therapy in Moderate to Severe Psoriasis From a Public Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy